An interventional study of Donepezil and Placebo in Alzheimer's Disease, sponsored by Pfizer. Terminated at 8 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2013-09-12.
Sponsored by Pfizer · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.
Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 52nd largest by enrollment of the 58 interventional ones that give a count, is one of 2 that started in 2010, is one of 6 with no phase, and was the 31st registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 50+
Eisai Inc.
Ages 50–85
By country, each count listing its studies:
Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 79 across the 58 interventional studies. Of the 56 that completed or were terminated, 21 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 60 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
101 studies in Alzheimer Disease by Pfizer: 1 open now, 1 under way, none of them phase 3. Of 99 finished, 40 (40%) have results posted.
Among the 101 studies in Alzheimer Disease by Pfizer, this one is the 76th largest by enrollment of the 94 interventional ones that give a count, is one of 8 that started in 2010, is one of 3 with no phase, and was the 87th registered.
Pfizer’s Alzheimer Disease studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing donepezil in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 101 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
The study hypothesizes that donepezil will have a positive impact on brain blood flow deficits in subjects with memory deficits and/or mild dementia and that improvements in brain blood flow will be accompanied by improvements in memory.
Inclusion Criteria:
Type II diabetic subjects may be included provided that their disease and serum glucose values are controlled and being actively managed, as assessed by the PI using a fasting blood sugar and/or HgbA1C (per the PI's medical judgment in consultation with the Sponsor).
Exclusion Criteria:
Exclusions Related to Medications or Procedures
Use of medication(s) for cognitive enhancement ≤ 90 days before the first dose of study medication.
Non-prescription treatments for cognitive enhancement.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Donepezil
Drug: Placebo
5 mg tablets once daily for 7 days and then 10mg on 8th day
matching placebo
Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 1
Posterior cingulate cortex perfusion was measured by arterial spin labeling (ASL). ASL is a completely noninvasive magnetic resonance method to measure regional cerebral perfusion. Results are reported for average relative perfusion rate. Average relative perfusion rate is defined as the average absolute perfusion rate divided by the whole brain absolute perfusion rate at the same time point. Average absolute perfusion rate is the average of left absolute perfusion rate and right absolute perfusion rate at the same time point.
Time frame: Baseline, 4 hours post-dose on Day 1
Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 0 on Day 8
Posterior cingulate cortex perfusion was measured by ASL. ASL is a completely noninvasive magnetic resonance method to measure regional cerebral perfusion. Results are reported for average relative perfusion rate. Average relative perfusion rate is defined as the average absolute perfusion rate divided by the whole brain absolute perfusion rate at the same time point. Average absolute perfusion rate is the average of left absolute perfusion rate and right absolute perfusion rate at the same time point.
Time frame: Baseline, 1 minute post-dose (Hour 0) on Day 8
Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 8
Posterior cingulate cortex perfusion was measured by ASL. ASL is a completely noninvasive magnetic resonance method to measure regional cerebral perfusion. Results are reported for average relative perfusion rate. Average relative perfusion rate is defined as the average absolute perfusion rate divided by the whole brain absolute perfusion rate at the same time point. Average absolute perfusion rate is the average of left absolute perfusion rate and right absolute perfusion rate at the same time point.
Time frame: Baseline, 4 hours post-dose on Day 8
Change From Baseline in Arterial Spin Label (ASL) Perfusion at Hour 4 on Day 1 and at Hour 0, 4 on Day 8
Perfusion in anterior cingulate cortex, medial prefrontal cortex, precuneus, inferior parietal cortex and other regions of interest (whole brain gray, superior, medial and inferior temporal cortex; inferior and superior prefrontal cortex; insula, amygdala, thalamus, basal ganglia, hippocampus, Landau) was measured by ASL technique. ASL is a completely noninvasive magnetic resonance method to measure regional cerebral perfusion. Results are reported for relative perfusion rate. Relative perfusion rate is defined as the absolute perfusion rate divided by the whole brain absolute perfusion rate at the same time point.
Time frame: Baseline, 4 hours post-dose on Day 1, 1 minute post-dose (Hour 0), 4 hours post-dose on Day 8
Change From Baseline in CogState Continuous Paired Associate Learning (CPAL) at Hour 5 on Day 1 and at Hour 1, 5 on Day 8
CPAL: a cognitive test which assessed visual episodic learning. Participant was to learn and remember picture locations on the screen and was to tap the target on the central location to begin. As each picture was revealed, the participant was to remember where the picture was located and tap that location. After 4 pictures were placed correctly, second round started. In second round pictures remain in the same locations, but their order of presentation in the center of the screen was different to that of the first round (randomized). The same process was repeated for round 3 and round 4. The outcome was the number of errors made in correctly placing each of the 4 patterns in their location 4 times.
Time frame: Baseline, 5 hours post-dose on Day 1; 1, 5 hours post-dose on Day 8
Change From Baseline in Rey Auditory Verbal Learning Test (RAVLT): Immediate and Delayed Recall at Hour 5 on Day 8
RAVLT, in immediate recall (IR) list of 15 words (list A) was read aloud to participant 5 times followed by a test of spontaneous retrieval (A1 to A5). After fifth attempt a list of interference, comprising 15 words (list B) was read to participant followed by its retrieval (B1). After attempt B1 examiner asked individual to recall words from list A, without reading it again (A6). Score range: 0-105, higher scores=less impairment. Delayed recall (DR):after a 20-minute interval examiner asked individual to remember words from list A without reading this list; in recognition performance a list comprising 15 words from list A, 15 words from list B, 20 distracting words (similar to words in list A, B) was read to individual. Upon each word read aloud, individual asked to indicate if it belonged to list A, or not. Score range: 0-30, higher scores=less impairment.
Time frame: Baseline, 5 hours post-dose on Day 8
Change From Baseline in CogState Test Battery at Hour 5 on Day 1 and at Hour 0, 5 on Day 8
Computerized test battery used to assess detection and identification task. CogState detection task: a measure of simple reaction time, provided valid assessment of psychomotor function. Participants were required to press a "YES" response key as soon as they detected an event (a card turning face up presented in center of the computer screen). The software measured the response time to detect each event. CogState identification task: measure of choice reaction time, provided a valid assessment of visual attention. Participants were required to decide "YES" or "NO" as to whether the event met a predefined and unchanging criterion (is the color of the card red?) while the event (a card turning face up) occurred in the center of the computer screen. The software measured the speed and accuracy of each response.
Time frame: Baseline, 5 hours post-dose on Day 1; 1, 5 hours post-dose on Day 8
| Milestone | Donepezil | Placebo |
|---|---|---|
| Started | 10 | 8 |
| Completed | 9 | 6 |
| Not completed | 1 | 2 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Other | 1 | 1 |
Posterior cingulate cortex perfusion was measured by arterial spin labeling (ASL). ASL is a completely noninvasive magnetic resonance method to measure regional cerebral perfusion. Results are reported for average relative perfusion rate. Average relative perfusion rate is defined as the average absolute perfusion rate divided by the whole brain absolute perfusion rate at the same time point. Average absolute perfusion rate is the average of left absolute perfusion rate and right absolute perfusion rate at the same time point.
| ratio | Donepezil | Placebo |
|---|---|---|
| Baseline | 1.243 ± 0.2586 | 1.564 ± 0.2494 |
| Change at Hour 4 on Day 1 | 0.156 ± 0.5178 | -0.017 ± 0.3810 |
Posterior cingulate cortex perfusion was measured by ASL. ASL is a completely noninvasive magnetic resonance method to measure regional cerebral perfusion. Results are reported for average relative perfusion rate. Average relative perfusion rate is defined as the average absolute perfusion rate divided by the whole brain absolute perfusion rate at the same time point. Average absolute perfusion rate is the average of left absolute perfusion rate and right absolute perfusion rate at the same time point.
| ratio | Donepezil | Placebo |
|---|---|---|
| Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 0 on Day 8 | 0.263 ± 0.4872 | 0.093 ± 0.5624 |
Posterior cingulate cortex perfusion was measured by ASL. ASL is a completely noninvasive magnetic resonance method to measure regional cerebral perfusion. Results are reported for average relative perfusion rate. Average relative perfusion rate is defined as the average absolute perfusion rate divided by the whole brain absolute perfusion rate at the same time point. Average absolute perfusion rate is the average of left absolute perfusion rate and right absolute perfusion rate at the same time point.
| ratio | Donepezil | Placebo |
|---|---|---|
| Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 8 | -0.008 ± 0.2506 | -0.004 ± 0.3948 |
Perfusion in anterior cingulate cortex, medial prefrontal cortex, precuneus, inferior parietal cortex and other regions of interest (whole brain gray, superior, medial and inferior temporal cortex; inferior and superior prefrontal cortex; insula, amygdala, thalamus, basal ganglia, hippocampus, Landau) was measured by ASL technique. ASL is a completely noninvasive magnetic resonance method to measure regional cerebral perfusion. Results are reported for relative perfusion rate. Relative perfusion rate is defined as the absolute perfusion rate divided by the whole brain absolute perfusion rate at the same time point.
| ratio | Donepezil | Placebo |
|---|---|---|
| Baseline: Whole Brain Gray | 1.486 ± 0.1215 | 1.500 ± 0.0869 |
| Baseline: Superior Temporal Cortex | 1.749 ± 0.2774 | 1.773 ± 0.1732 |
| Baseline: Medial Temporal Cortex | 1.753 ± 0.3186 | 1.718 ± 0.2778 |
| Baseline: Inferior Temporal Cortex | 1.260 ± 0.4634 | 1.173 ± 0.4024 |
| Baseline: Medial Prefrontal Cortex | 1.488 ± 0.1830 | 1.709 ± 0.1441 |
| Baseline: Inferior Prefrontal Cortex | 1.381 ± 0.2205 | 1.486 ± 0.1673 |
| Baseline: Superior Prefrontal Cortex | 1.308 ± 0.1236 | 1.443 ± 0.2046 |
| Baseline: Inferior Parietal Cortex | 1.610 ± 0.2824 | 1.714 ± 0.1628 |
| Baseline: Insula | 1.390 ± 0.1785 | 1.533 ± 0.2130 |
| Baseline: Precuneus | 1.357 ± 0.1904 | 1.505 ± 0.2781 |
| Baseline: Anterior Cingulate Cortex | 1.236 ± 0.2265 | 1.442 ± 0.1753 |
| Baseline: Amygdala | 1.067 ± 0.3025 | 1.256 ± 0.2966 |
| Baseline: Thalamus | 1.417 ± 0.4886 | 1.468 ± 0.3061 |
| Baseline: Basal Ganglia | 1.120 ± 0.2781 | 1.241 ± 0.2461 |
| Baseline: Hippocampus | 1.327 ± 0.2726 | 1.389 ± 0.1229 |
| Baseline: Landau | 1.916 ± 0.3753 | 2.025 ± 0.0940 |
| Change at Hour 4 on Day 1: Whole Brain Gray | 0.018 ± 0.2309 | 0.050 ± 0.1010 |
| Change at Hour 4 on Day 1:Superior Temporal Cortex | 0.031 ± 0.3430 | 0.023 ± 0.3002 |
| Change at Hour 4 on Day 1: Medial Temporal Cortex | -0.066 ± 0.5297 | -0.006 ± 0.2549 |
| Change at Hour 4 on Day 1:Inferior Temporal Cortex | -0.052 ± 0.6289 | 0.090 ± 0.2734 |
| Change at Hour 4 on Day 1:Medial Prefrontal Cortex | 0.035 ± 0.2704 | -0.164 ± 0.2054 |
| Change at Hour4 on Day1:Inferior Prefrontal Cortex | 0.143 ± 0.1987 | -0.061 ± 0.2299 |
| Change at Hour4 on Day1:Superior Prefrontal Cortex | 0.064 ± 0.2702 | -0.062 ± 0.2361 |
| Change at Hour 4 on Day 1:Inferior Parietal Cortex | -0.054 ± 0.2411 | -0.016 ± 0.1848 |
| Change at Hour 4 on Day 1: Insula | 0.154 ± 0.2813 | 0.096 ± 0.3276 |
| Change at Hour 4 on Day 1: Precuneus | -0.024 ± 0.3002 | 0.053 ± 0.2952 |
| Change at Hour 4 on Day1:Anterior Cingulate Cortex | 0.118 ± 0.2168 | 0.173 ± 0.2709 |
| Change at Hour 4 on Day 1: Amygdala | 0.187 ± 0.5504 | 0.175 ± 0.3785 |
| Change at Hour 4 on Day 1: Thalamus | 0.244 ± 0.5697 | -0.038 ± 0.2209 |
| Change at Hour 4 on Day 1: Basal Ganglia | 0.292 ± 0.4557 | 0.014 ± 0.1761 |
| Change at Hour 4 on Day 1: Hippocampus | 0.128 ± 0.2115 | 0.036 ± 0.2915 |
| Change at Hour 4 on Day 1: Landau | -0.051 ± 0.3923 | -0.033 ± 0.1952 |
| Change at Hour 0 on Day 8: Whole Brain Gray | 0.058 ± 0.1024 | 0.028 ± 0.1569 |
| Change at Hour 0 on Day 8:Superior Temporal Cortex | 0.051 ± 0.2678 | 0.038 ± 0.3095 |
| Change at Hour 0 on Day 8: Medial Temporal Cortex | -0.015 ± 0.3095 | -0.052 ± 0.2575 |
| Change at Hour 0 on Day 8:Inferior Temporal Cortex | 0.084 ± 0.6856 | -0.012 ± 0.3842 |
| Change at Hour 0 on Day 8:Medial Prefrontal Cortex | -0.198 ± 0.4168 | -0.173 ± 0.3050 |
| Change at Hour0 on Day8:Inferior Prefrontal Cortex | 0.043 ± 0.3353 | 0.010 ± 0.2188 |
| Change at Hour0 on Day8:Superior Prefrontal Cortex | -0.152 ± 0.3120 | -0.019 ± 0.2863 |
| Change at Hour 0 on Day 8:Inferior Parietal Cortex | 0.005 ± 0.5185 | -0.106 ± 0.2009 |
| Change at Hour 0 on Day 8: Insula | 0.103 ± 0.2679 | 0.154 ± 0.1816 |
| Change at Hour 0 on Day 8: Precuneus | 0.055 ± 0.4065 | 0.059 ± 0.3475 |
| Change at Hour 0 on Day8:Anterior Cingulate Cortex | 0.279 ± 0.4424 | 0.167 ± 0.3681 |
| Change at Hour 0 on Day 8: Amygdala | 0.170 ± 0.5388 | 0.083 ± 0.4233 |
| Change at Hour 0 on Day 8: Thalamus | 0.195 ± 0.6486 | -0.063 ± 0.4992 |
| Change at Hour 0 on Day 8: Basal Ganglia | 0.243 ± 0.3925 | 0.040 ± 0.3106 |
| Change at Hour 0 on Day 8: Hippocampus | 0.170 ± 0.2832 | 0.047 ± 0.2551 |
| Change at Hour 0 on Day 8: Landau | -0.030 ± 0.5354 | -0.105 ± 0.2642 |
| Change at Hour 4 on Day 8: Whole Brain Gray | 0.010 ± 0.1286 | -0.022 ± 0.0945 |
| Change at Hour 4 on Day 8:Superior Temporal Cortex | 0.126 ± 0.3065 | -0.037 ± 0.1319 |
| Change at Hour 4 on Day 8: Medial Temporal Cortex | -0.103 ± 0.2852 | -0.110 ± 0.2551 |
| Change at Hour 4 on Day 8:Inferior Temporal Cortex | -0.194 ± 0.5644 | -0.102 ± 0.3114 |
| Change at Hour 4 on Day 8:Medial Prefrontal Cortex | 0.111 ± 0.3606 | -0.038 ± 0.2262 |
| Change at Hour4 on Day8:Inferior Prefrontal Cortex | -0.031 ± 0.2477 | -0.001 ± 0.2342 |
| Change at Hour4 on Day8:Superior Prefrontal Cortex | 0.225 ± 0.3460 | -0.007 ± 0.1348 |
| Change at Hour 4 on Day 8:Inferior Parietal Cortex | -0.175 ± 0.4557 | -0.017 ± 0.1560 |
| Change at Hour 4 on Day 8: Insula | 0.148 ± 0.1477 | 0.078 ± 0.2317 |
| Change at Hour 4 on Day 8: Precuneus | -0.110 ± 0.3846 | 0.074 ± 0.3035 |
| Change at Hour 4 on Day8:Anterior Cingulate Cortex | 0.180 ± 0.2939 | 0.062 ± 0.1423 |
| Change at Hour 4 on Day 8: Amygdala | 0.097 ± 0.4984 | 0.019 ± 0.3100 |
| Change at Hour 4 on Day 8: Thalamus | -0.124 ± 0.5028 | -0.077 ± 0.5330 |
| Change at Hour 4 on Day 8: Basal Ganglia | 0.084 ± 0.3393 | -0.066 ± 0.2787 |
| Change at Hour 4 on Day 8: Hippocampus | 0.041 ± 0.2770 | 0.017 ± 0.1225 |
| Change at Hour 4 on Day 8: Landau | -0.208 ± 0.3152 | 0.008 ± 0.1418 |
CPAL: a cognitive test which assessed visual episodic learning. Participant was to learn and remember picture locations on the screen and was to tap the target on the central location to begin. As each picture was revealed, the participant was to remember where the picture was located and tap that location. After 4 pictures were placed correctly, second round started. In second round pictures remain in the same locations, but their order of presentation in the center of the screen was different to that of the first round (randomized). The same process was repeated for round 3 and round 4. The outcome was the number of errors made in correctly placing each of the 4 patterns in their location 4 times.
| errors | Donepezil | Placebo |
|---|---|---|
| Baseline (n=9, 8) | 46.222 ± 28.7436 | 37.625 ± 17.8641 |
| Change at Hour 5 on Day 1 (n=9, 8) | 4.333 ± 24.0936 | -2.625 ± 28.9084 |
| Change at Hour 1 on Day 8 (n=9, 6) | -5.444 ± 31.9653 | -15.833 ± 15.8293 |
| Change at Hour 5 on Day 8 (n=9, 6) | 2.000 ± 16.3325 | -8.000 ± 17.4126 |
RAVLT, in immediate recall (IR) list of 15 words (list A) was read aloud to participant 5 times followed by a test of spontaneous retrieval (A1 to A5). After fifth attempt a list of interference, comprising 15 words (list B) was read to participant followed by its retrieval (B1). After attempt B1 examiner asked individual to recall words from list A, without reading it again (A6). Score range: 0-105, higher scores=less impairment. Delayed recall (DR):after a 20-minute interval examiner asked individual to remember words from list A without reading this list; in recognition performance a list comprising 15 words from list A, 15 words from list B, 20 distracting words (similar to words in list A, B) was read to individual. Upon each word read aloud, individual asked to indicate if it belonged to list A, or not. Score range: 0-30, higher scores=less impairment.
| units on a scale | Donepezil | Placebo |
|---|---|---|
| Baseline: Total IR (n=9, 8) | 25.667 ± 7.3144 | 27.000 ± 9.3960 |
| Baseline: Total DR (n=9, 8) | 2.444 ± 2.3511 | 2.375 ± 2.1998 |
| Change at Hour 5 on Day 8:Total IR (n=9, 6) | 3.333 ± 4.1833 | 5.667 ± 4.3665 |
| Change at Hour 5 on Day 8: Total DR (n=9, 6) | 0.444 ± 1.9437 | 0.333 ± 3.0111 |
Computerized test battery used to assess detection and identification task. CogState detection task: a measure of simple reaction time, provided valid assessment of psychomotor function. Participants were required to press a "YES" response key as soon as they detected an event (a card turning face up presented in center of the computer screen). The software measured the response time to detect each event. CogState identification task: measure of choice reaction time, provided a valid assessment of visual attention. Participants were required to decide "YES" or "NO" as to whether the event met a predefined and unchanging criterion (is the color of the card red?) while the event (a card turning face up) occurred in the center of the computer screen. The software measured the speed and accuracy of each response.
| log10 milliseconds | Donepezil | Placebo |
|---|---|---|
| Baseline: Detection Task (n=9, 8) | 2.572 ± 0.1192 | 2.542 ± 0.0953 |
| Baseline: Identification Task (n=9, 8) | 2.708 ± 0.0635 | 2.727 ± 0.0540 |
| Change at Hour 5 on Day 1: Detection Task (n=9, 8) | 0.002 ± 0.0931 | 0.024 ± 0.0706 |
| Change at Hour5 on Day1:Identification Task(n=9,8) | 0.020 ± 0.0355 | 0.012 ± 0.0371 |
| Change at Hour 0 on Day 8: Detection Task (n=9, 6) | 0.004 ± 0.1184 | -0.032 ± 0.0512 |
| Change at Hour0 on Day8:Identification Task(n=9,6) | 0.005 ± 0.0630 | 0.004 ± 0.0493 |
| Change at Hour 5 on Day 8: Detection Task (n=9, 6) | -0.005 ± 0.1001 | 0.004 ± 0.0508 |
| Change at Hour5 on Day8:Identification Task(n=9,6) | 0.034 ± 0.0782 | 0.004 ± 0.0625 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Donepezil | — | 0/10 (0%) | 3/10 (30%) |
| Placebo | — | 0/8 (0%) | 2/8 (25%) |
| Event | Donepezil | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/10 | 1/8 |
| FatigueGeneral disorders | 0/10 | 1/8 |
| ExcoriationInjury, poisoning and procedural complications | 0/10 | 1/8 |
| Sensory disturbanceNervous system disorders | 0/10 | 1/8 |
| Abdominal discomfortGastrointestinal disorders | 1/10 | 0/8 |
| AstheniaGeneral disorders | 1/10 | 0/8 |
| Age Continuous(years) | Donepezil | Placebo | Total |
|---|---|---|---|
| Mean | 74.7 ± 9.6 | 70.6 ± 6.9 | 72.9 ± 8.5 |
| Sex: Female, Male(Participants) | Donepezil | Placebo | Total |
|---|---|---|---|
| Female | 5 | 6 | 11 |
| Male | 5 | 2 | 7 |
The record gives a start of Jul 2010, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil